Related references
Note: Only part of the references are listed.Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study
Hyun-Jae Kang et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2021)
Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists
Shizuya Yamashita et al.
ATHEROSCLEROSIS (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Probucol attenuates lipopolysaccharide-induced leukocyte recruitment and inflammatory hyperalgesia: effect on NF-κB activation and cytokine production
Amanda Z. Zucoloto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
A. Michael Lincoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination
R. Krishna et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation
Shizuya Yamashita et al.
CURRENT OPINION IN LIPIDOLOGY (2016)
Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease
Shizuya Yamashita et al.
Journal of Atherosclerosis and Thrombosis (2016)
Did we abandon probucol too soon?
Shizuya Yamashita et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
Jordan Fulcher et al.
LANCET (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Probucol Suppresses Macrophage Infiltration and MMP Expression in Atherosclerotic Plaques of WHHL Rabbits
Shen Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2014)
Effect of Probucol on Antioxidant Properties of HDL in Patients with Heterozygous Familial Hypercholesterolemia
Miwako Inagaki et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Probucol Attenuates Inflammation and Increases Stability of Vulnerable Atherosclerotic Plaques in Rabbits
Tingting Li et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Where are we with probucol: A new life for an old drug?
Shizuya Yamashita et al.
ATHEROSCLEROSIS (2009)
Probucol markedly reduces HDL phospholipids and elevated preβ1-HDL without delayed conversion into α-migrating HDL: Putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling
Takashi Miida et al.
ATHEROSCLEROSIS (2008)
Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet
T. Yoshikawa et al.
HORMONE AND METABOLIC RESEARCH (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Probucol [4,4′-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl) phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice
Ben J. Wu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits
Shao-cai Hong et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2007)
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis
Mitsuhiro Yokoyama et al.
LANCET (2007)
Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism
K Hirano et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia
D Marks et al.
ATHEROSCLEROSIS (2003)
Comparison of the effects of α-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits
JH Bräsen et al.
ATHEROSCLEROSIS (2002)
Effects of Probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia - Fukuoka Atherosclerosis Trial (FAST)
Y Sawayama et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Share Paper
